<DOC>
	<DOCNO>NCT02549651</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy MEDI4736 alone combination either tremelimumab AZD9150 adult subject relapse refractory dIffuse large B-cell lymphoma .</brief_summary>
	<brief_title>MEDI4736 Alone Combination With Tremelimumab AZD9150 Adult Subjects With Diffuse Large B-cell Lymphoma ( D4190C00023 )</brief_title>
	<detailed_description>This multicenter , open-label , dose-escalation dose-expansion study MEDI4736 monotherapy combination either tremelimumab AZD9150 . The objective describe dose-limiting toxicity , determine maximum tolerate dose , evaluate safety , tolerability , efficacy , immunogenicity , pharmacokinetics , pharmacodynamics MEDI4736 monotherapy combination either tremelimumab AZD9150 adult subject relapse refractory diffuse large B-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . Histologically confirm relapsed refractory diffuse large Bcell lymphoma ( DLBCL ) treat 5 prior line therapy ( dose escalation ) 3 prior line therapy ( dose expansion ) , include least 1 rituximabcontaining chemotherapy regimen 3 . Eastern Cooperative Group ( ECOG ) performance status 0 1 4 . Measurable disease International Working Group ( IWG ) response criterion lymphoma 5 . Adequate organ marrow function 1 . Previous immunemediated therapy 2 . Prior autologous allogeneic stem cell transplant . Subjects receive ASCT &gt; 100 day prior first dose ineligible available curative option fail ASCT eligible . 3 . Documented current central nervous system involvement 3 . Active prior document autoimmune inflammatory disease within 3 year , exception 4 . Concurrent prior conventional investigational anticancer therapy , within 28 day prior first dose study medication ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>tremelimumab</keyword>
	<keyword>AZD9150</keyword>
	<keyword>anti-PD-L1</keyword>
	<keyword>anti-CTLA-4</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>IMTC</keyword>
	<keyword>STAT3</keyword>
</DOC>